Celltrion's 'Uplima', "Signed Public Insurance Contracts with Major US PBMs"

Celltrion has entered the U.S. market with 'Yuflyma,' a biosimilar (biopharmaceutical generic) of 'Humira' (active ingredient adalimumab) developed by Celltrion and overseas sales handled by Celltrion Healthcare.

Celltrion's Humira biosimilar 'Yuflyma'
[Photo by Celltrion Healthcare]

On the 1st, Celltrion Healthcare announced, "At the end of last month, we signed a rebate contract to list Yuflyma as a preferred drug in the public insurance market of one of the major U.S. prescription benefit managers (PBMs)." However, the company stated that the target company and detailed contract terms will be disclosed after completing the subsequent administrative procedures following the contract signing.

With the imminent expiration of Humira's patent in the U.S. market, biosimilar developers have competitively started launching Humira biosimilars in the U.S. market since last month. This marks the beginning of a battle to capture a massive market worth $18.619 billion (approximately 25 trillion KRW) as of last year. However, concerns arose that Yuflyma and another domestically developed biosimilar, Samsung Bioepis's 'Hadlima,' might fail to secure market share as they were not initially listed in the formularies of major PBMs.

However, after Hadlima was included in the formulary of Prime Therapeutics, the 6th largest PBM in the U.S., on the 13th, Yuflyma also succeeded in securing listing contracts with major PBMs, signaling the start of full-scale market share competition. Celltrion Healthcare added, "We are currently negotiating with multiple PBMs and will continue to expand discussions with channels that align with our company strategy to list Yuflyma in insurance markets covering 40% of the U.S. population within this year, doing our best to achieve this goal.

This content was produced with the assistance of AI translation services.